Lymphoma, Hodgkin (CA209655) Observational

For a patient to be eligible for participation in this study, all of the following criteria must apply.

• Men and women ≥ 18 years of age.
• Histologically confirmed diagnosis of Classical Hodgkin Lymphoma (cHL).
• Patients who are treatment-naïve or are within ± 2 weeks of Day 1 of Cycle 1 of any line of therapy at time of enrollment.
  • Patients must be within ± 2 weeks of Day 1 of the first cycle of any line of therapy to enroll; a cycle is practice-defined for chemotherapy, targeted therapy, or immunotherapy-based regimens.
  • Patients enrolled, who receive anti-cancer therapy, and who go on to receive only supportive, palliative, hospice, or end-of-life care remain on study and should not be discontinued from follow-up.
• Any Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status (PS).
• Patients must have available medical records for the date of diagnosis of cHL.
• Patients must have available medical records documenting any prior treatment and treatment dates for the Hodgkin lymphoma, including chemotherapy, radiation, surgery and other anticancer therapy received.
• Patients must consent to use their FPFE tissue blocks, blood or serum samples, (obtained via SOC visits) for exploratory analyses.

A patient will not be eligible for participation in this study if any of the following criteria apply.

• Patients with unknown date of diagnosis of cHL.
• Patients whose prior therapy and dates of therapy (eg, surgery, radiation, or drug therapy) are unknown.
• Any other (non-HL) active malignancy for which the patient is receiving treatment.
• Patients participating in a clinical study that does not allow enrollment into a noninterventional study.
• At time of enrollment, patients who are receiving supportive, palliative, hospice or end-of-life care only and not receiving anti-cancer therapy will be excluded.
  • Patients enrolled who receive anti-cancer therapy, and who go on to receive only supportive, palliative, hospice, or end-of-life care remain on study and should not be discontinued from follow-up.

To learn more, visit ClinicalTrials.Gov

Study Type

Observational

Principal Investigator(s)

Asim Pati, MD

Sponsor(s)

Bristol-Myers Squibb